Cascara sagrada, aloe rule
This article was originally published in The Tan Sheet
Executive Summary
OTC laxative drug products containing cascara sagrada or aloe that were in interstate commerce as of Nov. 5 can be sold until stock is depleted, FDA says. However, such drugs cannot be introduced into interstate commerce after that date, when FDA's final rule classifying the ingredients as Category II in OTC laxatives took effect. Agency is completing responses to petitions by AHPA and others requesting stay of rule's effective date and enforcement action. Reg does not cover dietary supplements containing the ingredients, FDA notes...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.